Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice

Cited by papers we hold 9

• Mitochondrial dysfunction in neurodegenerative disorders: Potential therapeutic application of mitochondrial transfer to central nervous system-residing cells · 2023
  No notice
• Impaired dopamine release in Parkinson’s disease · 2023
  No notice
• Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions · 2023
  No notice
• “LRRK2: Autophagy and Lysosomal Activity” · 2020
  No notice
• Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease · 2020
  No notice
• LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis · 2020
  No notice
• Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease · 2019
  Corrected
• Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives · 2018
  No notice
• Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.